NAD+ Injection Dosing Protocol

NAD+ (Nicotinamide Adenine Dinucleotide) injection delivers a naturally occurring molecule directly into your body. NAD+ is found in every living cell and is involved in hundreds of processes related to energy production, DNA repair, gene regulation, and aging. It's technically a coenzyme (a helper molecule that enzymes need to function), not a peptide — but it's widely used alongside peptide protocols because of its injectable format and shared focus on longevity and cellular health.

At the molecular level, NAD+ is built from two connected building blocks (nucleotides) — one containing nicotinamide and one containing adenine, linked by phosphate groups. Its key feature is that it flips back and forth between two forms: NAD+ (the active, oxidized form) and NADH (the used, reduced form). This back-and-forth shuttling is what makes it essential for your cells' energy-production pathways.

The therapeutic rationale is based on age-associated NAD+ decline across tissues including skin, blood, liver, muscle, and brain. Lower NAD+ is associated with mitochondrial dysfunction, weaker DNA repair capacity, and cellular aging hallmarks. Injectable NAD+ bypasses digestive metabolism that affects oral precursor delivery and can produce rapid systemic availability.

Most human clinical trials target oral NAD+ precursors (NR and NMN), which generally show favorable safety and dose-dependent blood NAD+ increases. Direct injectable NAD+ has a smaller published trial base.

NAD+ injection is not FDA-approved for any therapeutic indication. It is available as a compounded preparation. All information on this page is educational and research-reference only.

The table below outlines a common NAD+ injection dosing protocol for subcutaneous (SubQ) administration. Most people start at the Assessment dose and work up gradually. The Loading Protocol is an alternative intensive approach — it uses higher daily doses over a shorter period and typically requires closer monitoring. Choose the path that matches your experience level and tolerance.

This table shows you how much bacteriostatic (BAC) water to add to each NAD+ vial size, what concentration you'll get, and exactly how much liquid to draw for common doses. Find your vial size in the left column, then read across to your target dose.

NAD+ injection side effects are often dose- and rate-dependent, and many are manageable through conservative titration and slower administration.

Common SubQ effects: Nausea, headache, flushing or warmth, and temporary fatigue are frequently reported during early titration, especially with higher starting doses.

Injection site reactions: Localized stinging, burning, redness, or small temporary nodules can occur. Slower injection and site rotation can reduce irritation.

IV-specific effects: Rapid IV administration has historically been associated with headache or shortness of breath, while slower infusion rates are generally better tolerated.

Sleep disruption: Because NAD+ can feel stimulatory for some users, late-day dosing may worsen insomnia.

Metabolic and hepatic considerations: Very high-dose protocols may increase processing burden. Periodic monitoring of liver and metabolic markers may be considered in extended protocols.

Contraindications: Avoid during pregnancy or breastfeeding, severe hepatic or renal impairment, active malignancy (theoretical concern), and known hypersensitivity to formulation components.

Most published clinical trials on NAD+ boosting have tested oral supplements (NR and NMN) rather than direct NAD+ injection. This matters because the evidence base for injectable NAD+ specifically is much smaller. The table below includes both oral precursor trials and the limited injectable data, so you can see the full picture. Look at the "Phase" column to distinguish between injection studies and oral supplement studies.

Clinical evidence for NAD+ boosting is strongest for oral precursors (NR and NMN), with repeated findings of dose-dependent NAD+ increases and generally favorable safety. Direct injectable NAD+ has comparatively limited published human outcome data, so many SubQ protocols remain practitioner- and community-derived while larger clinical datasets continue to evolve.

There are three main ways to boost NAD+ levels: injecting NAD+ directly, or taking an oral supplement (NMN or NR) that your body converts into NAD+. Each approach has trade-offs in convenience, speed, evidence quality, and cost. The table below compares all three so you can see how they stack up.

NAD+ injection, NMN, and NR target the same NAD+ repletion goal through different delivery and conversion pathways.

NAD+ injection offers the most direct delivery but has less clinical-trial depth. NR currently has the strongest human data, while NMN evidence is expanding.

Many practitioner models use oral precursor baseline support plus periodic injectable NAD+ for acute repletion windows.

See the NMN protocol, NR protocol, Ipamorelin protocol, CJC-1295 protocol and BPC-157 protocol for compound-specific guides.